M I Cooiman1,2, L Kleinendorst3, E O Aarts4, I M C Janssen4,5, H K Ploos van Amstel6, A I Blakemore7,8, E J Hazebroek4, H J Meijers-Heijboer9,3, B van der Zwaag6, F J Berends4, M M van Haelst9,3. 1. Department of Bariatric Surgery, Rijnstate Hospital Arnhem/Vitalys, Wagnerlaan 55, 6815 AD, Arnhem, the Netherlands. mcooiman@rijnstate.nl. 2. Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. mcooiman@rijnstate.nl. 3. Department of Clinical Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. 4. Department of Bariatric Surgery, Rijnstate Hospital Arnhem/Vitalys, Wagnerlaan 55, 6815 AD, Arnhem, the Netherlands. 5. Department of Surgery, Nederlandse Obesitas Kliniek West, The Hague, The Netherlands. 6. Department of Genetics, University Medical Center Utrecht, Utrecht, the Netherlands. 7. Department of Life Sciences, Brunel University London, London, UK. 8. Section of Investigative Medicine, Imperial College London, London, UK. 9. Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Abstract
BACKGROUND: Mutations in the leptin-melanocortin pathway genes are known to cause monogenic obesity. The prevalence of these gene mutations and their effect on weight loss response after bariatric surgery are still largely unknown. OBJECTIVE: To determine the prevalence of genetic obesity in a large bariatric cohort and evaluate their response to bariatric surgery. METHODS: Mutation analysis of 52 obesity-associated genes. Patient inclusion criteria were a BMI > 50 kg/m2, an indication for revisional surgery or an early onset of obesity (< 10 years of age). RESULTS: A total of 1014 patients were included, of whom 30 (3%) were diagnosed with genetic obesity, caused by pathogenic heterozygous mutations in either MC4R, POMC, PCSK1, SIM1, or PTEN. The percentage total body weight loss (%TBWL) after Roux-en-Y gastric bypass (RYGB) surgery was not significantly different for patients with a mutation in MC4R, POMC, and PCSK1 compared with patients lacking a molecular diagnosis. Of the confirmed genetic obesity cases, only patients with MC4R mutations receiving a sleeve gastrectomy (SG) showed significantly lower %TBWL compared with patients lacking a molecular diagnosis, during 2 years of follow-up. CONCLUSIONS: In this cohort of morbid obese bariatric patients, an estimated prevalence of monogenic obesity of 3% is reported. Among these patients, the clinical effects of heterozygous mutations in POMC and PCSK1 do not interfere with the effectiveness of most commonly performed bariatric procedures within the first 2 years of follow-up. Patients with MC4R mutations achieved superior weight loss after primary RYGB compared with SG.
BACKGROUND: Mutations in the leptin-melanocortin pathway genes are known to cause monogenic obesity. The prevalence of these gene mutations and their effect on weight loss response after bariatric surgery are still largely unknown. OBJECTIVE: To determine the prevalence of genetic obesity in a large bariatric cohort and evaluate their response to bariatric surgery. METHODS: Mutation analysis of 52 obesity-associated genes. Patient inclusion criteria were a BMI > 50 kg/m2, an indication for revisional surgery or an early onset of obesity (< 10 years of age). RESULTS: A total of 1014 patients were included, of whom 30 (3%) were diagnosed with genetic obesity, caused by pathogenic heterozygous mutations in either MC4R, POMC, PCSK1, SIM1, or PTEN. The percentage total body weight loss (%TBWL) after Roux-en-Y gastric bypass (RYGB) surgery was not significantly different for patients with a mutation in MC4R, POMC, and PCSK1 compared with patients lacking a molecular diagnosis. Of the confirmed genetic obesity cases, only patients with MC4R mutations receiving a sleeve gastrectomy (SG) showed significantly lower %TBWL compared with patients lacking a molecular diagnosis, during 2 years of follow-up. CONCLUSIONS: In this cohort of morbid obese bariatric patients, an estimated prevalence of monogenic obesity of 3% is reported. Among these patients, the clinical effects of heterozygous mutations in POMC and PCSK1 do not interfere with the effectiveness of most commonly performed bariatric procedures within the first 2 years of follow-up. Patients with MC4R mutations achieved superior weight loss after primary RYGB compared with SG.
Authors: K Dogan; B Betzel; J Homan; E O Aarts; N Ploeger; H de Boer; Th J Aufenacker; C J H M van Laarhoven; I M C Janssen; F J Berends Journal: Obes Surg Date: 2014-11 Impact factor: 4.129
Authors: Lotte Kleinendorst; Maarten P G Massink; Mellody I Cooiman; Mesut Savas; Olga H van der Baan-Slootweg; Roosje J Roelants; Ignace C M Janssen; Hanne J Meijers-Heijboer; Nine V A M Knoers; Hans Kristian Ploos van Amstel; Elisabeth F C van Rossum; Erica L T van den Akker; Gijs van Haaften; Bert van der Zwaag; Mieke M van Haelst Journal: J Med Genet Date: 2018-07-03 Impact factor: 6.318
Authors: I Sadaf Farooqi; Julia M Keogh; Giles S H Yeo; Emma J Lank; Tim Cheetham; Stephen O'Rahilly Journal: N Engl J Med Date: 2003-03-20 Impact factor: 91.245
Authors: Ivy R Aslan; Guilherme M Campos; Melissa A Calton; Daniel S Evans; Raphael B Merriman; Christian Vaisse Journal: Obes Surg Date: 2011-07 Impact factor: 4.129
Authors: John W M Creemers; Hélène Choquet; Pieter Stijnen; Vincent Vatin; Marie Pigeyre; Sigri Beckers; Sandra Meulemans; Manuel E Than; Loïc Yengo; Maithé Tauber; Beverley Balkau; Paul Elliott; Marjo-Riitta Jarvelin; Wim Van Hul; Luc Van Gaal; Fritz Horber; François Pattou; Philippe Froguel; David Meyre Journal: Diabetes Date: 2011-12-30 Impact factor: 9.461
Authors: Gry B N Nordang; Øyvind L Busk; Kristian Tveten; Hans Ivar Hanevik; Anne Kristin M Fell; Jøran Hjelmesæth; Øystein L Holla; Jens K Hertel Journal: Mol Genet Metab Date: 2017-03-29 Impact factor: 4.797
Authors: J Philippe; P Stijnen; D Meyre; F De Graeve; D Thuillier; J Delplanque; G Gyapay; O Sand; J W Creemers; P Froguel; A Bonnefond Journal: Int J Obes (Lond) Date: 2014-06-03 Impact factor: 5.095
Authors: Bryn S Moore; Uyenlinh L Mirshahi; Evan A Yost; Ann N Stepanchick; Michael D Bedrin; Amanda M Styer; Kathryn K Jackson; Christopher D Still; Gerda E Breitwieser; Glenn S Gerhard; David J Carey; Tooraj Mirshahi Journal: PLoS One Date: 2014-04-04 Impact factor: 3.240
Authors: Alejandro Campos; Lizeth Cifuentes; Anas Hashem; Bradley Busebee; Maria D Hurtado-Andrade; Maria L Ricardo-Silgado; Alison McRae; Alan De la Rosa; Fauzi Feris; Joshua T Bublitz; Donald Hensrud; Michael Camilleri; Todd A Kellogg; Jeanette E Eckel-Passow; Janet Olson; Andres Acosta Journal: Obes Surg Date: 2022-06-03 Impact factor: 3.479
Authors: Niels Vos; Sabrina M Oussaada; Mellody I Cooiman; Lotte Kleinendorst; Kasper W Ter Horst; Eric J Hazebroek; Johannes A Romijn; Mireille J Serlie; Marcel M A M Mannens; Mieke M van Haelst Journal: Curr Diab Rep Date: 2020-07-30 Impact factor: 4.810
Authors: Lotte Kleinendorst; Ozair Abawi; Bibian van der Voorn; Mieke H T M Jongejan; Annelies E Brandsma; Jenny A Visser; Elisabeth F C van Rossum; Bert van der Zwaag; Mariëlle Alders; Elles M J Boon; Mieke M van Haelst; Erica L T van den Akker Journal: PLoS One Date: 2020-05-08 Impact factor: 3.240